Literature DB >> 24059494

Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment.

Jian-Quan Luo1, Lu-Yan Wang, Fa-Zhong He, Ning-Ling Sun, Gen-Fu Tang, Jia-Gen Wen, Zhi-Ying Luo, Zhao-Qian Liu, Hong-Hao Zhou, Xiao-Ping Chen, Wei Zhang.   

Abstract

AIM: The mineralocorticoid receptor (MR; also known as NR3C2) plays important roles in the modulation of blood pressure. The effect of NR3C2 polymorphisms on antihypertensive response to enalapril was investigated. PATIENTS &
METHODS: Two hundred and seventy nine essential hypertension patients treated with enalapril were genotyped for two NR3C2 tagSNPs, rs5522 and rs2070950, by Sequenom MassArray™ technology.
RESULTS: The reductions in diastolic blood pressure (DBP) were significantly greater in AA homozygotes compared with AG+GG genotype carriers for the rs5522 polymorphism (p = 0.009), and the reductions in DBP were greater in GG homozygotes compared with GC+CC genotype carriers for the rs2070950 polymorphism, with marginal significance (p = 0.065). Stepwise multiple regression analysis indicated that significant predictors of DBP reduction were baseline DBP (p < 0.001), waist:hip ratio (p = 0.001) and rs5522 genotype (p = 0.003).
CONCLUSION: NR3C2 rs5522 affects blood pressure response to enalapril treatment and may serve as a useful pharmacogenomic marker of antihypertensive response to enalapril in essential hypertension patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24059494     DOI: 10.2217/pgs.13.173

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  9 in total

Review 1.  Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction.

Authors:  Guanghong Jia; Yan Jia; James R Sowers
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-10-29       Impact factor: 5.187

Review 2.  An update on the pharmacogenetics of treating hypertension.

Authors:  V Fontana; M R Luizon; V C Sandrim
Journal:  J Hum Hypertens       Date:  2014-08-28       Impact factor: 3.012

3.  Peripheral Blood Transcripts Predict Preoperative Obstructive Total Anomalous Pulmonary Venous Connection.

Authors:  Zunmin Wan; Xiaohong Li; Jinghua Sun; Xiaohua Li; Zhongzhen Liu; Haojian Dong; Qing Zhou; Hailong Qiu; Jinjin Xu; Tingyu Yang; Wen-Jing Wang; Yanqiu Ou
Journal:  Front Cardiovasc Med       Date:  2022-05-31

Review 4.  Current therapeutic approaches to cardio-protection in hypertension.

Authors:  David Parra; Augustus Hough
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

5.  NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial.

Authors:  Leanne Dumeny; Orly Vardeny; Frank Edelmann; Burkert Pieske; Julio D Duarte; Larisa H Cavallari
Journal:  Pharmacotherapy       Date:  2021-10-12       Impact factor: 4.705

6.  Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure.

Authors:  Neven M Sarhan; Mohamed H Shahin; Nihal M El Rouby; Lamia M El-Wakeel; Mohamed H Solayman; Taimour Langaee; Hazem Khorshid; Mona F Schaalan; Nagwa A Sabri; Larisa H Cavallari
Journal:  Clin Transl Sci       Date:  2019-10-21       Impact factor: 4.689

7.  WNT3A rs752107(C > T) Polymorphism Is Associated With an Increased Risk of Essential Hypertension and Related Cardiovascular Diseases.

Authors:  Huan Ren; Jian-Quan Luo; Fan Ouyang; Li Cheng; Xiao-Ping Chen; Hong-Hao Zhou; Wei-Hua Huang; Wei Zhang
Journal:  Front Cardiovasc Med       Date:  2021-07-12

Review 8.  The role of renin-angiotensin aldosterone system related micro-ribonucleic acids in hypertension.

Authors:  Hui-Bo Wang; Jun Yang
Journal:  Saudi Med J       Date:  2015-10       Impact factor: 1.484

9.  Long Non-Coding RNA Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Promotes Hypertension by Modulating the Hsa-miR-124-3p/Nuclear Receptor Subfamily 3, Group C, Member 2 (NR3C2) and Hsa-miR-135a-5p/NR3C2 Axis.

Authors:  Liju Luo; Yu Wang; Pengfei Hu; Jiale Wu
Journal:  Med Sci Monit       Date:  2020-03-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.